Cite
HARVARD Citation
Gümüş, M. et al. (2023). Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study. Cancer. 129 (1), pp. 118-129. [Online].